Brought to you by 
FOPO nets $90.8mm for Sequenom
24 Jan 2011
Executive Summary
In a follow-on public offering, Sequenom Inc. (diagnostic testing and genetic analysis systems) has netted $90.8mm by selling 16.1mm shares (including the overallotment) at $6. Part of the proceeds will be specifically used for validation studies of the company's Trisomy 21 DNA test, which assesses pregnant women who are at a high risk for carrying a fetus with the chromosomal abnormality.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FOPO nets $90.8mm for Sequenom
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice